

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 199879672 B2**
(10) Patent No. **727080**

(54) Title
Calcium blockers to treat proliferative vitreoretinopathy

(51)⁶ International Patent Classification(s)
A61K 031/44

(21) Application No: 199879672 (22) Application Date: 1998.06.15

(87) WIPO No: W099/00129

(30) Priority Data

(31) Number	(32) Date	(33) Country
60/051962	1997.06.30	US

(43) Publication Date : 1999.01.19
(43) Publication Journal Date : 1999.03.11
(44) Accepted Journal Date : 2000.11.30

(71) Applicant(s)
Allergan Sales, Inc.

(72) Inventor(s)
Evan B Dreyer

(74) Agent/Attorney
DAVIES COLLISON CAVE,GPO Box 3876,SYDNEY NSW 2001

(56) Related Art
US 5623051
TRENDS PHARMACOLOGICAL SCIENCES 13:291-296 (1992)
SCIENCE 248:597-603 (1992)

OPI DATE 19/01/99 APPLN. ID 79672/98
AOJP DATE 11/03/99 PCT NUMBER PCT/US98/12414



AU9879672

INTERNATIONAL

(51) International Patent Classification 6: A61K 31/44		A1	(11) International Publication Number: WO 99/00129
			(43) International Publication Date: 7 January 1999 (07.01.99)
(21) International Application Number: PCT/US98/12414		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 15 June 1998 (15.06.98)			
(30) Priority Data: 60/051,962 30 June 1997 (30.06.97) US			
(71)(72) Applicant and Inventor: DREYER, Evan, B. [US/US]; 504 Conshohocken State Road, Penn Valley, PA 19072 (US).			
(74) Agent: FREEMAN, John, W.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).		Published With international search report.	
7) Applicant: Allergan Sales, Inc. 2525 Dupont Drive, Irvine, California 92612 USA.			
(54) Title: CALCIUM BLOCKERS TO TREAT PROLIFERATIVE VITREORETINOPATHY			
(57) Abstract Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administration to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.			

- 1 -

CALCIUM BLOCKERS TO TREAT PROLIFERATIVE VITREORETINOPATHYBackground of the Invention

This application relates to preventing, controlling reducing and/or treating proliferative vitreoretinopathy.

Proliferative vitreoretinopathy (including epiretinal membrane formation) is a potentially devastating ophthalmic condition that can lead to blindness. It can develop after any penetration of the eye -- surgical or traumatic. Predisposing conditions therefore include, but are not limited to, penetrating trauma, retinal tears, traction detachments, vitrectomy, and intraocular surgery. Any ophthalmic condition that precipitates or permits migration of retinal pigment epithelium or glial cells can lead to the development of proliferative vitreoretinopathy. See Machamer (1978) *British J. Ophthal.* 62:737; Hilton et al. (1983) *Ophthalmology* 90:121.

Summary of the Invention

I have discovered that glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells. The invention features the use of glutamate antagonists to reduce or control retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal pigment epithelium and/or glial migration in a concentration effective to reduce such migration.

While I do not wish to be bound to any specific theory, I conclude that one or more of the several types of calcium-permeable CNS ion channels mentioned below can be involved in controlling such migration, including: a) the various aspects of the NMDA (N-methyl-D-aspartate)

- 2 -

receptor channel complex; b) the voltage-dependent Ca^{2+} channels; and c) other channels directly coupled to glutamate (or excitatory amino acid) receptors. Such channels are reviewed in: Sommer, B. and Seeburg, P.H.

- 5 "Glutamate receptor channels: novel properties and new clones" *Trends Pharmacological Sciences* 13:291-296 (1992); Nakanishi, S., "Molecular Diversity of glutamate receptors and implications for brain function", *Science* 248:597-603 (1992).

10 One aspect of the invention generally features a method of treating, preventing, or reducing proliferative vitreoretinopathy in a patient by administering to the patient's retina an effective amount of a compound that reduces CNS neuronal damage incident to (associated with)
15 calcium ion influx.

A second aspect of the invention features treating, preventing, or reducing proliferative vitreoretinopathy in a patient by administering to the patient's retina an effective amount of at least one of
20 the compounds listed in one or more of Tables 2-5. below.

A third aspect of the invention features treating preventing or reducing proliferative vitreoretinopathy in a patient by administering to the patient's retina an effective amount of a compound that reduces glutamate
25 related retinal cell migration, proliferation, or both.

The compound may be one of the so-called NMDA antagonists -- i.e., it reduces neuronal damage mediated by the NMDA receptor complex. Alternatively, the compound antagonizes neuronal damage mediated by the
30 voltage-dependent calcium channel. Other useful compounds are those which limit release of glutamate from cells or reduce the intracellular neurotoxic consequences of glutamate interaction with cell membrane glutamate receptors. Preferably, the compound crosses the blood-
35 retinal barrier.

- 3 -

The patient may be anyone who has experienced, or is at risk for experiencing, penetrating trauma, retinal tear, traction detachment, vitrectomy, or intraocular surgery. The compound may be administered to the patient
5 topically, orally, or intravitreally, as well as by other routes described below. It may be administered chronically, i.e., over an extended period of a month or even six months or years.

The invention preferably will be used to treat
10 patients having proliferative vitreoretinopathy or to treat patients prophylactically to avoid that condition. Preferably, the agent is administered over an extended period (e.g., at least six months and preferably at least one year). Those at risk for developing proliferative
15 vitreoretinopathy include patients who have experienced penetrating trauma, retinal tears, traction detachments, vitrectomy, or intraocular surgery.

Particularly preferred compounds are antagonists of the NMDA receptor-channel complex. The term "NMDA
20 receptor antagonists" includes several sub-types of NMDA antagonists including: a) channel blockers -- i.e., antagonists that operate uncompetitively to block the NMDA receptor channel; b) receptor antagonists -- antagonists that compete with NMDA to act at the NMDA
25 binding site; c) agents acting at either the glycine co-agonist site or any of several modulation sites such as the zinc site, the magnesium site, the redox modulatory site, or the polyamine site; d) agents which inhibit the downstream effects of NMDA receptor stimulation, such as
30 agents that inhibit activation of protein kinase C activation by NMDA stimulation, antioxidants, and agents that decrease phosphatidylinositol metabolism.

Other compounds that are useful in the invention include voltage-dependent calcium channel antagonists,
35 e.g. those which exert a substantial direct effect on

- 4 -

glutamate toxicity mediated by the L-type voltage dependent Ca^{++} channel in that they produce a statistically significant result in experiments measuring glutamate induced effects by the general method described
5 in Karschian and Lipton, *J. Physiol.* **418**: 379-396 (1989) or by other techniques for measuring antagonism of the L-type Ca^{++} channel known to those in the art. (We contrast the direct effect so measured with the secondary effects of excitotoxicity mediated by other channels, which in turn
10 causes flow through the voltage dependent Ca^{++} channels.) Particular candidate compounds include Class I voltage dependent Ca^{++} channel antagonists, e.g., phenylalkylamines.

Preferably, the compounds used cross the blood-
15 retina barrier and can be administered chronically. Other useful agents act as antagonists of non-NMDA receptors (glutamate receptor types other than the NMDA receptor complex discussed above), and include agents which block ionotropic glutamate receptors or interact
20 with metabotropic glutamate receptors (Nakanishi, *supra*). Still other agents act to limit (reduce) release of glutamate from cells, thereby acting upstream from the glutamate receptors in the excitatory neurotoxicity process. Still other agents may act by blocking
25 downstream effects of glutamate receptor stimulation, e.g., the intracellular consequences of glutamate interaction with a cell membrane glutamate receptor, such as agents (like dantrolene) that block the rise in intracellular calcium following stimulation of membrane
30 glutamate receptors.

The most preferred compounds are those capable of crossing the blood-retinal barrier; these compounds may be administered orally, intravenously, or topically and cross intervening barriers including the blood-retina
35 barrier to reach the retinal ganglion cells. Compounds

- 5 -

that do not freely cross the blood-retina barrier are less preferred; these compounds may be administered intravitreally to the retina. In the case of compounds that have an intermediate ability to cross the blood-
5 retina barrier, the mode of administration will depend on the dosage required and other factors.

Among the preferred compounds are amantadine derivatives (e.g., memantine, amantadine, and rimantadine), nitroglycerin, dextorphan,
10 dextromethorphan, and CGS-19755. See generally, the compounds listed in Table 2.

The invention is useful for the reduction or prevention (including prophylactic treatment) of damage as a result of proliferative vitreoretinopathy.

15 Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

Description of the Preferred Embodiments

Selection of Antagonists

20 In view of our discovery that glutamate is associated with proliferative vitreoretinopathy, the invention features antagonists having certain specific characteristics: the ability to cross the blood-retina barrier; and the ability to be administered chronically.
25 Within those guidelines, any suitable antagonist of the glutamate induced excitotoxicity may be used in accordance with the invention. As mentioned, in preferred embodiments, N-methyl-D-aspartate (NMDA) subtype of glutamate receptor-channel complex may be used
30 to reduce or prevent proliferative vitreoretinopathy-related injury. Many antagonists of the NMDA receptor have been identified (Watkins et al., Trends in Pharmacological Sci. 11:25, 1990, hereby incorporated by reference). There are several recognized sub-types of

- 6 -

NMDA receptor including: a) channel blockers -- i.e., antagonists that operate non-competitively to block the NMDA receptor channel; b) receptor antagonists -- antagonists that compete with NMDA, acting at the NMDA binding site; c) agents acting at either the glycine co-agonist site or any of several modulation sites such as the zinc site, the magnesium site, the redox modulatory site, or the polyamine site; d) agents which inhibit the downstream effects of NMDA receptor stimulation such as agents that inhibit activation of protein kinase C activation by NMDA stimulation, antioxidants, and agents that decrease phosphatidylinositol metabolism.

Other compounds that are useful in this invention include non-NMDA receptor antagonists, such as agents which block other types of ionotropic glutamate receptors or interact with metabotropic glutamate receptors; voltage-dependent calcium channel antagonists (against L, N, T, and P type channels) (Bean, B.P. Annu. Rev. Physiol. 51:367-384 (1989); Hess, P. Annu. Rev. Neurosci. 13:337-356 (1990)), and are described in greater detail below; and agents which act to decrease the release of glutamate, thereby acting upstream in the excitatory neurotoxicity process.

Table 1, below, lists various suitable NMDA and non-NMDA receptors which do not operate via the voltage-dependent Ca^{++} ion channel. Tables 2-4 list antagonists of the voltage dependent Ca^{++} channel, which can be used by themselves in connection with the first aspect of the invention, and which can also be used in combination with other antagonists in the second aspect of the invention.

Table 1, Page 1

- 7 -

NMDA Antagonists	NMDA Antagonists	NMDA Antagonists
1. Competitive NMDA Antagonists (act at agonist binding site)	2. Channel Blockers (Un-Competitive NMDA Antagonists)	3. Antagonists at Glycine Site of the NMDA Receptor
CGS-19755 (CIBA-GEIGY) and other piperidine derivatives, D-2-amino-5-phosphovalerate, D-2-amino-7-phosphonoheptanoate (APT)	MK-801 (Dizocilpine) and other derivatives of dibenzocycloheptene (Merck)	Kynurenate, 7-chloro-kynurenate, 5,7-chloro-kynurenate, thio-derivatives, and other derivatives. (Merck)
CPP [[3-(2-carboxypiperazin-4-yl-propyl)-1-phosphonic acid]]	Sigma receptor ligands, e.g. Dextrophan, dextromethorphan and morphinan derivatives (Hoffman La Roche) such as caraniphen and timentazole (which also block calcium channels)	Indole-2-carboxylic acid
LY 274614, CGP39551, CGP37849, LY233053, LY233536	Ketamine, Tilcetamine and other cyclohexanes	DNQX
O-phosphobornoserine	Phencyclidine (PCP) and derivatives, and pyrazine compounds	Quinoxaline or oxadiazole derivatives including CNQX, NBQX
MDL100,453	Memantine, amantadine, rimantadine and derivatives	Glycine partial agonist (e.g. Hoechst-Roussel P-9939)
	CNS 1102 (and related bi- and tri-substituted guanidines)	
	Diamines	
	Conantokin peptide from Conus geographus	
	Agatoxin-489	

Table 1, Page 2

- 8 -

NMDA Antagonists	NMDA Antagonists	NMDA Antagonists
4. Polyamine Site of NMDA Receptor	5. Redox Site of NMDA Receptor	6. Other Non-Competitive NMDA Antagonists
Arcaïne and related biguanidines and biogenic polyamines	Oxidized and reduced glutathione	Hoechst 831917189
Ifenprodil and related drugs	PQQ (pyrroloquinoline quinone)	SKB Carvedilol
Diethylenetriamine SL 82,0715	Compounds that generate Nitric Oxide (NO) or other oxidation states of nitrogen monoxide (NO ⁺ , NO ⁻) including those listed in the box below	
1,10-diaminodecane (and related inverse agonists)	Nitroglycerin and derivatives, Sodium Nitroprusside, and other NO generating listed on p. 5 of this table	
	Nitric oxide synthase (NOS) Inhibitors: Arginine analogs including N -mono-methyl-L-arginine (NMA); N -amino-L-arginine (NAA); N -nitro-L-arginine (NNA); N -nitro-L-arginine methyl ester; N-iminoethyl-L-orithine	
	Flavin Inhibitors: diphenyliodonium; Calmodulin inhibitors, trifluoperazine	
	Calcineurin Inhibitors, e.g., FK-506 (inhibits calcineurin and thus NOS diaphosphorylase)	

Table 1, Page 3

- 9 -

Inhibitors of Downstream Effects of NMDA	Inhibitors of Downstream Effects of NMDA	Non-NMDA Receptor Antagonists
7. Agents to inhibit protein kinase C activation by NMDA stimulation (Involved in NMDA toxicity)	8. Downstream effects from Receptor Activation	9A. Non-NMDA antagonists (Competitive)
MDL 27,266 (Merrill Dow) and triazolo-one derivatives	8a. To decrease phosphatidylinositol metabolism	CNQX, NBQX, YM900, DNQX, PD140532
Monosialogangliosides (eg GM1 of Fidia Corp.) and other ganglioside derivatives LIGA20, LIGA4 (may also effect calcium extrusion via calcium ATPase)	kappa opioid receptor agonist: U50488(Upjohn) and dynorphin	AMOA (2-amino-3-[3-9-carboxymethoxy-5-methoxyisoxazol-4-yl]propionate)
	kappa opioid receptor agonist: PD117302, CI-977	2-phosphophonomethyl phenylalanine derivatives, i.e. 5-ethyl, 5-methyl, 5-trifluoromethyl
	8b. To decrease hydrogen peroxide and free radical injury, eg antioxidants	
	21-aminosteroid (azaroids) such as U74500A, U75412E and U74006F	9B. Non-NMDA Non competitive antagonists
	U74389F, FLE26749, Trolox (water soluble alpha tocopherol), 3,5-dialkoxy-4-hydroxy-benzylamines	CYKIS2466
	Compounds that generate Nitric Oxide (NO) or other oxidation states of nitrogen monoxide (NO+, NO-) including those listed in the box below	Evans Blue
	Nitroglycerin and derivatives, Sodium Nitroprusside, and other NO generating listed on p. 5 of this table	
	Nitric oxide synthase (NOS) inhibitors: Arginine analogs including N-mono-methyl-L-arginine (NMA); N-amino-L-arginine (NAA); N-nitro-L-arginine (NNA); N-nitro-L-arginine methyl ester; N-iminoethyl-L-ornithine	

Table 1, Page 4

- 10 -

Agents Active at Metabotropic Glutamate Receptors	Decrease glutamate release	Drugs to decrease intracellular calcium following glutamate receptor stimulation
10a. Blockers of Metabotropic Glutamate Receptors	11. Agents to decrease glutamate release	12a. Agents to decrease intracellular calcium release
AP3 (2-amino-3-phosphonopropionic acid)	Adenosine, and derivatives, e.g. cyclohexyladenosine	Dantrolene (sodium dantrolene); Ryanodine (or ryanodine + caffeine)
10b. Agonists of Metabotropic Glutamate Receptors	CNS1145	12b. Agents inhibiting intracellular Calcium-ATPase
(1S, 3R)-1-Amino-cyclopentane-1,3-dicarboxylic acid [(1S,3R)-ACPD], commonly ref as 'trans'-ACPD	Conopeptides: SNX-111, SNX-183, SNX-230	Thapsigargin, cyclopiazonic acid, BHQ ([2,5-di-(tert-butyl)-1,4-benzohydroquinone; 2,5-di-(tert-butyl)-1,4-benzohydroquinone])
	Omega-Aga-IVA, toxin from venom of funnel web spider	
	Compounds that generate Nitric Oxide (NO) or other oxidation states of nitrogen monoxide (NO ⁺ , NO ⁻) including those listed in the box below	
	Nitroglycerin and derivatives, Sodium Nitroprusside, and other NO generating listed on p. 5 of this table	
	Nitric oxide synthase (NOS) Inhibitors: Arginine analogs including N-monomethyl-L-arginine (NMA); N-ε-amino-L-arginine (NAA); N-nitro-L-arginine (NNA); N-nitro-L-arginine methyl ester; N-iminoethyl-L-ornithine	

- 11 -

Table 1, Page 5

Additional NO-generating compounds
Isosorbide dinitrate (isordil)
S-nitrosocaptopril (SnoCap)
Serum albumin coupled to nitric oxide (SA-NO)
Cathepsin coupled to nitric oxide (cathepsin-NO)
Tissue plasminogen activator coupled to NO (TPA-NO)
SIN-1 (also known as SDF1 or molsidomine)
Iron-nitrosyl complexes (e.g., nitrosyl-iron complexes, with iron in the Fe ²⁺ state)
Nicorandil

- 12 -

TABLE 2

<u>Antagonists of the Voltage Dependent Calcium Channels (N, L, T, P and other types)</u>	
	dihydropyridines (e.g., nimodipine)
5	phenylalkylamines (e.g., verapamil, (S)-emopamil, D-600, D-888)
	benzothiazepines (e.g., diltiazem and others)
	bepiridil and related drugs
	diphenylbutylpiperdines
10	diphenylpiperazines (e.g., flunarizine/cinnarizine series)
	HOE 166 and related drugs
	fluspirilene and related drugs
	toxins and natural compounds (e.g., snail toxins -
15	ω conotoxin GVIA and GVIIA, maitotoxin, taicatoxin, tetrandine, hololena toxin, plectreury's toxin, funnel-web spider venom and its toxin fraction, agatoxins including ω -agatoxin IIIA and ω -agatoxin IVA.
20	

TABLE 3

<u>DIHYDROPYRIDINE CALCIUM CHANNEL ANTAGONISTS</u>		
	nifedipine	KW3049
25	niludipine	oxodipine
	PY108-068 (darodipine)	CD349
	mesudipine	TC81
	GX 1048	YM-09730-5 or (4S)DHP
	floridine	MDL72567
30	nitrendipine	Ro18-3981
	nisoldipine	DHP-218
	nimodipine	nilvadipine
	nicardipine	amlodipine
	felodipine	8363-S
35	PN200-110 (Isradipine)	iodipine
	CV4093	azidopine

- 13 -

TABLE 4

OTHER CALCIUM CHANNEL ANTAGONISTS

	diclofurime	D-600
	pimozide	D-888
5	prenylamine	Smith Kline 9512
	fendiline	ranolazine
	perhexiline	lidoflazine
	mioflazine	CERM-11956
	flunarizine/cinnarizine	R-58735
10	series	R-56865
	verapamil	amiloride
	dilfiazine	phenytoin
	dipropervine	thioridazine
15	(S)-emopamil	tricyclic antidepressants

In Vitro Assay

An antagonist may be tested for utility in the method of the invention by monitoring its effect on proliferative retinopathy as follows.

20 Cultured fibroblasts will be injected into the vitreous of the rabbit eye. After two weeks, the degree of vitreopathy can be assessed histologically. At the time of the initial insult, the animals will be treated with the compound under consideration.

25 Such models are well known. A few examples (hereby incorporated by reference) included Kiumura et al. *Human Gene Therapy*, 7:799-808 (1996); Sakamoto et al., *Ophthalmology* 102:1417-1421 (1995); Handa et al. *Experimental Eye Research* 62:689-696 (1996); Berger et al. *37*: 2318-1325 (1996); de Souza et al. *Ophthalmologica* 209: 212-216 (1995); Nakagawa et al. *Ophthalmology & Visual Science* 36:2388-2395 (1995); Steinhorst et al. *Archive for Clinical & Experimental Ophthalmology* 232:347-354 (1994).

35 Use

An effective receptor antagonist will cause a decrease in proliferative vitreoretinopathy. As described above, the preferred compounds which cross the blood-retinal barriers are preferably administered
5 topically or orally in known, physiologically acceptable vehicles including tablets, liquid excipients and suspensions. Those skilled in the art will appreciate how to formulate acceptable therapeutics.

Antagonists may be compounded into a
10 pharmaceutical preparation, using pharmaceutical compounds well-known in the art; the exact formulation and dosage of the antagonist compound depends upon the route of administration. Generally, the effective daily dose of the antagonists will range from 0.01 to 1000
15 mg/kg.

Other Embodiments

Other embodiments are within the following claims. In the method of the invention, a useful compound may be administered by any means that allows the compound access
20 to the retina. The compounds useful in the method include antagonists of excitatory amino acid receptors (both NMDA and non-NMDA subtypes) that act to reduce retinal cell migration or proliferation or reduce binding of glutamate to the NMDA receptor. The antagonists can
25 act at a modulatory site or a co-agonist site or by blocking the chain of events initiated by receptor activation.

Other embodiments are within the following claims.

Prior Art

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.



The claims defining the invention are as follows:

1. A method of treating, preventing, or reducing proliferative vitreoretinopathy in a patient by administering to the patient's retina an effective amount
5 of a compound that reduces CNS neuronal damage incident to calcium ion influx.

2. A method of treating or preventing proliferative vitreoretinopathy in a patient by administering to the patient's retina an effective amount
10 of at least one of the compounds listed in one or more of Tables 1-4.

3. A method of treating or preventing proliferative vitreoretinopathy in a patient by administering to the patient's retina an effective amount
15 of a compound that reduces glutamate related retinal cell migration, proliferation, or both.

4. The method of claim 1, 2, or 3 in which the compound inhibits glutamate-related proliferation of retinal cells.

20 5. The method of claim 1, 2, or 3 in which the compound inhibits glutamate-related migration of retinal cells.

6. The method of claim 1, 2, or 3 in which the compound controls NMDA receptor complex-mediated
25 activity.

7. The method of claim 1, 2, or 3 in which the compound controls the voltage-dependent calcium channel activity.



8. The method of claim 1, 2, or 3 in which the compound crosses the blood-retinal barrier.

9. The method of claim 1, 2, or 3 in which the
5 patient has or will experience penetrating trauma,
retinal tear, traction detachment, vitrectomy, or
intraocular surgery.

10. The method of claim 1, 2, or 3, said compound
being administered to said patient topically.

10 11. The method of claim 1, 2, or 3, said compound
being administered to said patient orally.

12. The method of claim 1, 2, or 3, said compound
being administered to said patient intravitreally.

13. The method of claim 1 or 2 wherein said
15 compound is administered chronically.

14. The method of claim 1, 2, or 3 wherein said
compound limits release of glutamate from cells.

15. The method of claim 1, 2 or 3, wherein said
compound controls glutamate interaction with cell
20 membrane glutamate receptors.

16. Use of a compound which reduces CNS
neuronal damage incident to calcium ion influx in the
preparation of a medicament for the treatment,
prophylaxis or reduction of proliferative
vitreoretinopathy.

17. Use of at least one of the compounds listed
in one or more of Tables 1-4 in the preparation of a
medicament for the treatment or prophylaxis of
proliferative vitreoretinopathy.



18. Use of compound which reduces glutamate related retinal cell migration, proliferation, or both in the preparation of a medicament for the treatment or prophylaxis of proliferative vitreoretinopathy.

DATED this 27th day of September 2000

Allergan Sales, Inc.

by its Patent Attorneys

DAVIES COLLISON CAVE

2
2
2

3
3
3

4
4
4

